TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction

Background Blockade of the programmed cell death protein 1 (PD-1) immune checkpoint (ICB) is revolutionizing cancer therapy, but little is known about the mechanisms governing its expression on CD8 T cells. Because PD-1 is induced during activation of T cells, we set out to uncover regulators whose...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gal Markel, Michal J Besser, Eytan Ruppin, Oscar Krijgsman, Daniel S Peeper, Judit Díaz-Gómez, Ettai Markovits, David W Vredevoogd, Georgi Apriamashvili, Pierre L Levy, Sanju Sinha, Zowi R Huinen, Nils L Visser, Beaunelle de Bruijn, Julia Boshuizen, Susan E van Hal-van Veen, Maarten A Ligtenberg, Onno B Bleijerveld, Chun-Pu Lin, Santiago Duro Sánchez, Juan Simon Nieto, Alex van Vliet, Maarten Altelaar
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-11-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/11/e010145.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction

Similar Items